Answers are grounded in this paper and cite their sources.
Structural and pharmacological profiling reveals how diverse ligands activate complement receptor C3aR across species, indicating new avenues for drug design in inflammatory disorders.
The complement anaphylatoxin receptor, C3aR, is a prototypical G protein-coupled receptor (GPCR) that plays multi-faceted roles in immune regulation, pro-inflammatory responses, neuroimmune modulation, and host defense mechanisms against pathogens. Recent structural coverage has provided important insights into C3aR activation and signaling, however, confounding observations in the literature related to ligand efficacy and functional responses present a major challenge for drug discovery efforts. Here, we systematically and comprehensively profile a broad set of natural and synthetic ligands at C3aR, and demonstrate functional specialization in terms of species-specific pharmacology, receptor activation, and signaling-bias. Taking a lead from this, we determine seven cryo-EM structures of C3aR, and employ structure-guided site-directed mutagenesis studies to decode a convergent molecular mechanism that orchestrates the recognition and efficacy of diverse agonists. This study elucidates key molecular insights into C3aR activation and signaling with direct implications for therapeutic design. The complement anaphylatoxin receptor, C3aR is a potential drug target in various inflammatory disorders. Here, authors present insights into its activation, signaling, and pharmacology that is likely to facilitate therapeutic design going forward.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: